The Denver II is not a suitable screening test for use in South African infants, and further research is required. There is a slight to moderate agreement between the Denver II and the BSID III tests. The Denver II is not accurate in identifying developmental delay. The agreement between the results of the two tests were represented by a Kappa value of 0.111 for the BSID III assessed as “at risk” (p = 0.014), and 0.423 for the BSID III assessed as “handicapped” (p < 0.000). The Denver II had a specificity greater than 90%.for both BSID III composite cutoff values. 8% and 44.0% for a 14 BSID III composite score cutoff of <85 (“at risk”), and <70 (“handicapped”) respectively. The sensitivity of the Denver II in identifying developmental delay was. Time Requirements: takes about 20-30 min to administer and interpret. Target Population and Ages: birth to 6 years of age. Type of Test: First-level comprehensive screening. The results of infants that had both a Denver II and a BSID III were assessed. Purpose: screening for developmental problems to confirm suspected problems using an objective measure to monitor children at risk for developmental delay. The study population consisted of both normal and high 10 risk neonates born between 1 July 2013 and 31 December 2015. This is a retrospective descriptive study. The Bayley Scales of Infant and Toddler Development III (BSID III) is used as a gold standard test, to determine the level of agreement between the two tests. This article aims at assessing the accuracy of the Denver II in identifying developmental delay 6 in high risk newborns. The Denver Developmental Screening Test II (Denver II) is used to assess the development of high risk newborns at a tertiary hospital in Johannesburg.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |